Abstracts tagged "corticosteroids"

Abstract Number: 348 • 2016 ACR/ARHP Annual Meeting
Bisphosphonates-Related Atypical Femur Fractures: 8 Years’ Experience in a Single Center
JungHee Koh¹, Seo Hwa Kim², Haneul Kim³, Min Kyung Chung³, Ji Hyeon Ju⁴ and Sung-Hwan Park⁴, ¹Seochogu, Banpodaero, 222, Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ²Division of Rheumatology,, Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, The Republic of, ³Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, The Republic of, ⁴Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: Patients with rheumatoid arthritis (RA) are diagnosed with osteoporosis earlier than those without, and are therefore exposed to bisphosphonates for longer. However, the increasing…
Abstract Number: 763 • 2016 ACR/ARHP Annual Meeting
Rituximab As a Corticosteroid-Sparing Agent in Patients with Systemic Lupus Erythematosus
Na Ri Kim¹, Jung Su Eun¹, Jong Wan Kang¹, Eon Jeong Nam¹ and Young Mo Kang², ¹Division of Rheumatology, Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea, Republic of
Background/Purpose : The treatment of active systemic lupus erythematosus (SLE) remains problematic because the current treatment regimen based on corticosteroids and immunosuppressive agents have significant…
Abstract Number: 1366 • 2016 ACR/ARHP Annual Meeting
Evidence Based Criteria for Corticosteroid Tapering/Discontinuation. an Analysis of the Paediatric Rheumatology International Trials Organization (PRINTO) Trial in New Onset Juvenile Dermatomyositis
Gabriella Giancane¹, Claudio Lavarello¹, Angela Pistorio¹, Francesco Zulian², Bo Magnusson², Tadej Avcin², Fabrizia Corona², Valeria Gerloni², Serena Pastore², Roberto Marini Sr.², Silvana Martino², Anne Pagnier², Michel Rodiere², Christine Soler², Valda Stanevicha², Rebecca ten Cate², Yosef Uziel², Jelena Vojinovic², Angelo Ravelli², Alberto Martini² and Nicolino Ruperto², ¹Pediatria II, Reumatologia, PRINTO, Istituto Giannina Gaslini, Genoa, Italy, ²Istituto Giannina Gaslini, Genoa, Italy
Background/Purpose: Corticosteroids in juvenile dermatomyositis (JDM) alone or in association with other immunosuppressive drugs, namely methotrexate (MTX) and cyclosporine (CSA), represent the first-line treatment option for…
Abstract Number: 1489 • 2016 ACR/ARHP Annual Meeting
Incident Hypertension and Associated Factors in a Hispanic Group with Rheumatoid Arthritis
Mariangelí Arroyo-Ávila¹, Ruth Fred-Jiménez², Naydi Pérez-Ríos³, Angel M Mayor⁴, Noelia Rodríguez-Pérez¹, Grissel Ríos¹ and Luis M. Vilá⁵, ¹Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, PR, ²Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico, ³Puerto Rico Clinical and Translational Research Consortium, University of Puerto Rico Medical Sciences Campus, San Juan, PR, ⁴Universidad Central Del Caribe, Puerto Rico Clinical and Translational Research Consortium, Bayamón, Puerto Rico, ⁵Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico
Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased incidence of cardiovascular disease. Hypertension is a major cardiovascular risk factor and it is one of…
Abstract Number: 2236 • 2016 ACR/ARHP Annual Meeting
Effects of Repository Corticotropin Injection on Medication Use in Patients with Rheumatologic Conditions: A Claims Data Study
Gihyun Myung¹, Winnie Nelson² and Maureen A. McMahon³, ¹Division of Rheumatology/Department of Internal Medicine, University of California-Los Angeles, Los Angeles, CA, ²Health Economics and Outcomes Research, Mallinckrodt Pharmaceuticals, Hampton, NJ, ³University of California-Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA
Background/Purpose: Repository corticotropin injection (RCI) may produce anti-inflammatory and immune-modulatory effects. This study examined the demographics of those who used RCI and the trends in…
Abstract Number: 2245 • 2016 ACR/ARHP Annual Meeting
Injectable Corticosteroid Use in Musculoskeletal Care Specialties
Gurjit S. Kaeley¹, Myint Thway¹ and Sunita Dodani², ¹Rheumatology, University of Florida College of Medicine, Jacksonville, Jacksonville, FL, ²Epidemiology, University of Florida, College of Medicine & College of Public Health and Health Professions, Gainesville, Jacksonville, FL
Background/Purpose: Injectable corticosteroids (IC) are widely used for joint and soft tissue injections. Although four main types of preparations are available, there is sparse evidence…
Abstract Number: 2266 • 2016 ACR/ARHP Annual Meeting
A Melanocortin Fusion Peptide (AQB-565) Optimized for Melanocortin Receptor Engagement Significantly Reduces Inflammation in an In Vivo model of Acute Gout
Ronald Berenson¹, Maura-Ann Matthews¹, Wayne Wallis², Raj Dua¹, Margaret Moore¹, Robert Terkeltaub³ and Christopher Clegg^1,4, ¹Aequus BioPharma, Inc., Seattle, WA, ²Dyad Life Sciences, LLC, Seattle, WA, ³Medicine-Rheumatology, University of California, San Diego, La Jolla, CA, ⁴TRIA Bioscience, Seattle, WA
Background/Purpose: The melanocortins (MCs) are endogenous peptides (including ACTH, α-MSH and γ-MSH), which bind 5 G protein-coupled receptors (MCRs 1 through 5) with varying affinity.…
Abstract Number: 2316 • 2016 ACR/ARHP Annual Meeting
Successful Treatment of Statin-Induced Autoimmune Myopathy without Corticosteroids
Geneviève Oligny Longpré¹, Yves Troyanov¹, Marvin J. Fritzler², José Ferreira¹, Ira N. Targoff³, Hélène Couture⁴, Océane Landon-Cardinal¹, Eric Rich¹, Josiane Bourré-Tessier⁵, Anne-Marie Mansour¹, Julie Drouin¹, Sandra Chartrand¹, Edith Villeneuve¹, Jean-Richard Goulet¹, Benjamin Ellezam⁶, Ana Maria Tsanaclis¹, Vincent Morin¹, Marie-Pierre Fournier-Gosselin¹ and Jean-Luc Senécal¹, ¹Université de Montréal, Montréal, QC, Canada, ²Medicine, University of Calgary, Calgary, AB, Canada, ³University of Oklahoma, Oklahoma City, OK, ⁴Université Laval, Québec, QC, Canada, ⁵Université de Montréal, Montreal, QC, Canada, ⁶Centre hospitalier universitaire Ste-Justine, Montréal, QC, Canada
Methods: Our study included all patients from the Université de Montréal AIM cohort (comprising four academic hospitals) with a documented anti-3-hydroxy-3-methylglutaryl-CoA reductase (anti-HMGCR) autoantibody. We selected…
Abstract Number: 1302 • 2015 ACR/ARHP Annual Meeting
Inflammation Signs on Magnetic Resonance Imaging in Chronic or Recurrent Gonarthritis Treated with Intra-Articular Infliximab or Corticosteroids
Gülsah Akdemir¹, Arie E. van der Bijl², Badelog J.E. de Lange-Brokaar³, T. W. J. Huizinga¹, Cornelia F. Allaart¹ and Margreet Kloppenburg³, ¹Rheumatology, LUMC, Leiden, Netherlands, ²Isala Klinieken, Zwolle, Netherlands, ³Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: To evaluate synovial inflammation on magnetic resonance imaging (MRI) before treatment and changes after treatment with intra-articular (i.a.) infliximab (IFX) or methylprednisolone (MP) injections…
Abstract Number: 1651 • 2015 ACR/ARHP Annual Meeting
Comparison of Oral Glucocorticoid (OGC)-Sparing Effects in Tocilizumab and Other Biologic Dmards Using Multilevel Models in an Administrative Health Care Claims Database
Brandon Arnieri¹, Khaled Sarsour¹, David Oliveri¹, Attila Pethö-Schramm², Avani Shah¹ and George Quartey¹, ¹Genentech, South San Francisco, CA, ²F. Hoffmann-La Roche, Basel, Switzerland
Background/Purpose : The current treatment paradigm in rheumatoid arthritis (RA) is to attempt to decrease, when clinically feasible, concomitant use of OGCs after their use…
Abstract Number: 1833 • 2015 ACR/ARHP Annual Meeting
Musculoskeletal Complications of Systemic Lupus Erythematosus: Risk Factors for and Prevalence of Avascular Necrosis and Osteoporosis
Maeve Gamble¹ and Janet E. Pope², ¹Medicine, University of Western Ontario, London, ON, Canada, ²University of Western Ontario, London, ON, Canada
Background/Purpose: Osteoporosis (OP) and avascular necrosis (AVN) are well-recognized musculoskeletal complications of systemic lupus erythematosus (SLE) and cause morbidity. Steroid therapy and the underlying disease…
Abstract Number: 1979 • 2015 ACR/ARHP Annual Meeting
Baseline Data on Patients Enrolled in a Randomized, Double-Blind Trial of Tocilizumab in Giant Cell Arteritis
Katie Tuckwell¹, Neil Collinson¹, Micki Klearman², Sophie Dimonaco¹, John H. Stone³ and on behalf of the GiACTA Investigators, ¹Roche Products Ltd., Welwyn Garden City, United Kingdom, ²Genentech, South San Francisco, CA, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: GiACTA, a randomized, double-blind, placebo-controlled trial of the interleukin-6 receptor alpha inhibitor tocilizumab (TCZ) in patients (pts) with giant cell arteritis (GCA), is the…
Abstract Number: 1990 • 2015 ACR/ARHP Annual Meeting
Corticosteroid Use in Idiopathic Aortitis: A Systematic Review
Nancy Maltez¹ and Nataliya Milman², ¹Internal Medicine, University of Ottawa, Ottawa, ON, Canada, ²Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada
Background/Purpose: Idiopathic aortitis (IA) is a poorly defined entity with no specific pathological or clinical criteria for its classification or diagnosis, except for the presence…
Abstract Number: 2537 • 2015 ACR/ARHP Annual Meeting
Prescription Medication Use in Sweden Among Pregnant Women with Systemic Lupus Erythematosus and General Population Comparators
Kristin Palmsten¹, Julia F Simard^2,3, Christina D Chambers^1,4 and Elizabeth V Arkema⁵, ¹Department of Pediatrics, University of California, San Diego, La Jolla, CA, ²Division of Epidemiology, Health Research and Policy Department, and Division of Immunology & Rheumatology, Department of Medicine, Stanford School of Medicine, Stanford, CA, ³Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Family Medicine and Public Health, University of California, San Diego, La Jolla, CA, ⁵Department of Medicine, Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: There is limited information regarding medication use patterns among pregnant women with systemic lupus erythematosus (SLE). We aimed to characterize trends of medications used…
Abstract Number: 3142 • 2015 ACR/ARHP Annual Meeting
Tocilizumab Enhances Regulatory T-Cell Activation and Proliferation in Giant Cell Arteritis
Chie Miyabe¹, Klemen Strle², Yoshishige Miyabe¹, John H. Stone^1,3, Andrew D. Luster^1,4 and Sebastian Unizony^1,5, ¹Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Allergy & Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Massachusetts General Hospital, Charlestown, MA, ⁵Rheumatology, Massachusetts General Hospital, Boston, MA
Background/Purpose : CD4+ T helper (Th) 17 cells, Th1 cells, and regulatory T-cells (Treg) contribute to the pathogenesis of giant cell arteritis (GCA). Interleukin (IL)-6,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.